Bonuses drive up compensation for Lilly’s top brass
Eli Lilly and Co. granted larger bonuses to its top five executives early this year, which boosted their 2012 compensation anywhere from 3 percent to 8 percent.
Eli Lilly and Co.
Articles
Court may decide if drugmakers can pay to delay generics
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
Profits at center of biosimilars debate
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
FDA probe of diabetes medications hurts drugmakers’ stock
Shares of several pharmaceutical companies that make diabetes medicines, including Eli Lilly, fell after U.S. regulators warned they are looking into potential risks of drugs in two classes of diabetes treatments.
Drugmakers, Interpol ramp up fight against fakes
More than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
Overseas tax savings for U.S. drugmakers under threat
Eli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits overseas. The strategy has drawn the ire of some legislators.
Lilly sues Genentech to invalidate Erbitux-related patents
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
Testosterone for diabetes may be new market for Lilly, others
Researchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
Lilly to expand partnership with diagnostic firm
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Lilly halts late-stage testing of rheumatoid arthritis drug
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
Lilly aims to submit five new drugs for approval
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
Lilly’s profit drops 4 percent, but beats analysts’ estimates
Price increases and sales gains helped Eli Lilly and Co. offset declining revenue from its former blockbuster Zyprexa in the fourth quarter, allowing the company to beat analysts' expectations and raise its 2013 profit forecast.
Lilly drug chosen for Alzheimer’s prevention study
Researchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.
Eli Lilly and Co.’s rebound bolsters endowment
The value of Lilly Endowment Inc.’s principal holding—Eli Lilly and Co. stock—has increased nearly $2 billion over the past two years, bolstering the private foundation’s philanthropic firepower after a decade of declining or stagnant assets.
Lilly’s Amyvid receives European approval
European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.
Lilly competitor gets backing on diabetes drug
Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.
Lilly settles with four sisters in DES cancer case
Four sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.
Drug sold by Lilly caused cancer, women claim at Boston trial
In opening statements Tuesday, a lawyer for Indianapolis-based Lilly told the jury there is no evidence the synthetic estrogen known as DES causes breast cancer in the daughters of women who took it.
Big drug deals expected to return in 2013
Pharmaceutical companies including Pfizer Inc., Bristol-Myers Squibb Co. and Eli Lilly and Co. could be ready to start making major acquisitions again.
Lilly’s 2013 profit forecast tops expectations
Eli Lilly and Co. forecasts its 2013 earnings will grow more than Wall Street expects even though the drugmaker will lose U.S. patent protection for two more key products in the new year.